grimlog,
Those two timelines were provided in the Quarterly.
Re RP11, the Quarterly advised that engagement with the FDA on the registrational study design would occur in Q2 2025. Not sure if that would be before or after they report the data from the Phase 1/2 studies to a conference in Utah between 4 & 8 May.
Re PKD, the Quarterly advised that they were expecting a regulatory response in February 2025.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.005(0.42%) |
Mkt cap ! $691.1M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.19 | $410.5K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15611 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |